NewsRoom Articles - Page 2 of 238

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

TuesdayJun 02, 2026 10:00 am

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

A new viral-based vector that can be inhaled into the lungs could boost the anti-cancer response of the body in patients diagnosed with advanced lung cancer. This new treatment could also restore sensitivity to immune checkpoint inhibitors among patients that had become unresponsive. The new investigational therapy, dubbed KB707, was developed by a team at Cleveland Clinic Cancer Institute. The treatment is based on a vector platform leveraging a modified herpes simplex virus that is non-replicating. The agent delivers cytokines IL-12 and IL-2 directly into the lungs once the patient inhales it. This delivery via inhalation helps to get the therapy into the microenvironment of the tumors in the lungs, and the…

MondayJun 01, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value…

MondayJun 01, 2026 9:00 am

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled…

FridayMay 29, 2026 10:00 am

US CDC Broadens Ebola Travel Ban to Include Green Card Holders

The Centers for Disease Control and Prevention (CDC) in the U.S. has extended the recently issued travel ban on individuals who have been to Uganda, South Sudan, and the Democratic Republic of Congo (DRC) during the past 21 days to now include green card holders. The reason given for this broadened ban is to prevent the disease from being brought into the country by legal permanent residents. The previous travel ban had excluded U.S. citizens, green card holders and other nationals and was to be in effect for 30 days. However, the CDC issued a notice including green card holders in that travel ban. Only…

ThursdayMay 28, 2026 10:00 am

Climate Change Amplifies Infectious Disease Risks, Experts Warn

According to advice published in the Netherlands last week, climate change is increasing the risk of not just infectious diseases but also cancer and heat stress. This concern has implications not just in the U.S. but globally as well. In their advisory that was issued on Thursday, the Scientific Climate Council and the Dutch Health Council caution that health impacts connected to climate change are increasing at a rate that hadn’t been previously expected. The two councils urge for additional protection for all people. They say if these extra protective measures aren’t speedily implemented, heat-linked fatalities due to climate change could multiply six-fold by 2050 in the Netherlands. The Netherlands isn’t the only country facing climate change, so…

ThursdayMay 28, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma is advancing a clinical-stage multiple sclerosis program targeting demyelination, a differentiated approach compared to many existing therapies focused primarily on immune modulation. The company maintains royalty participation and equity ownership exposure to unbuzzd(TM) while preserving pharmaceutical and medical-use rights to related formulations. Lucid-MS has completed Phase 1 safety studies and advanced into the IND submission stage ahead of a planned Phase 2 clinical trial in multiple sclerosis. Quantum BioPharma’s portfolio spans both therapeutic drug development and consumer-focused wellness products, creating multiple potential operational and…

WednesdayMay 27, 2026 12:00 pm

Earth Science Tech Inc. (ETST) Drives Shareholder Value Through Multi-Sector Diversification and Ongoing Buybacks

Earth Science Tech has positioned itself as a diversified healthcare holding company focused on pharmaceutical compounding, telemedicine, healthcare services, and strict capital allocation. The company recently completed a vertically integrated telehealth and pharmacy ecosystem through the launch of MyOnlineConsultation.com, with telemedicine capabilities supporting patient acquisition, while pharmacy operations drive high-margin recurring prescription-based revenue streams. Above all, Earth Science Tech emphasizes balance-sheet strength and capital discipline through ongoing share repurchase initiatives designed to reduce dilution and support shareholder value. The growing company operates multiple subsidiaries spanning compounding pharmacies, telehealth platforms, clinics, healthcare support services, real estate and cash management. Over the…

WednesdayMay 27, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’

GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows. Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage. A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients. The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor. Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the…

TuesdayMay 26, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity

OTLC completed a $12.5M monetization of its N2B CNS delivery system with Lunai Bioworks, targeting Alzheimer’s and biodefense applications The deal grants field-specific IP rights while preserving Oncotelic’s development in other CNS indications The move aligns with the rising industry focus on blood-brain barrier (“BBB”) bypass technologies and platform-based CNS drug delivery Oncotelic Therapeutics (OTCQB: OTLC) is advancing its position in one of biotechnology’s most persistent and commercially significant challenges: drug delivery to the central nervous system (“CNS”). As the industry increasingly recognizes the blood-brain barrier (“BBB”) as a primary constraint in neurological drug development, companies developing delivery-focused platforms are…